Clinical Trial Update: A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus [Phase 1]

View source ↗

Summary

Phase 1 trial updates tolerability of different doses of BI 3706674 in patients with advanced gastric and esophageal cancers; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• BI 3706674

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumor, KRAS Mutation | Phase 1 | Status: COMPLETED